Physician profile
John M Lawless
NPI 1275543571
$18,285.81
in general payments reported to CMS, 2019-2025
56 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,307 · 2020: $3,502 · 2021: $5,420 · 2022: $3,000 · 2023: $364 · 2024: $283 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,533.92 | 2019-2025 | Otezla, Krystexxa |
| Amarin Pharma, INC. | $1,490.29 | 2019-2022 | |
| Novo Nordisk INC | $1,453.85 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,422.48 | 2019-2024 | Farxiga |
| Abbvie INC. | $1,283.63 | 2019-2024 | |
| Glaxosmithkline, LLC. | $1,121.92 | 2019-2022 | |
| Lilly USA, LLC | $1,120.79 | 2019-2022 | |
| Allergan, INC. | $890.65 | 2019-2020 | |
| Esperion Therapeutics, INC. | $767.66 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $589.60 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $575.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $539.06 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $505.40 | 2019-2022 | |
| Pfizer INC. | $454.87 | 2019-2021 | |
| Astellas Pharma US INC | $418.13 | 2019-2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lawless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.